Michael Chan to Antineoplastic Agents
This is a "connection" page, showing publications Michael Chan has written about Antineoplastic Agents.
Connection Strength
0.378
-
Petty WJ, Urbanic JJ, Ahmed T, Hughes R, Levine B, Rusthoven K, Papagikos M, Ruiz JR, Lally BE, Chan M, Clark H, D'Agostino RB, Blackstock AW. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):527-535.
Score: 0.108
-
Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244.
Score: 0.096
-
Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg. 2012 May; 116(5):978-83.
Score: 0.070
-
Chan MD, McMullen KP. Multidisciplinary management of intracranial ependymoma. Curr Probl Cancer. 2012 Jan-Feb; 36(1):6-19.
Score: 0.069
-
Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, Pasche B, Watabe K. Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Res. 2016 09 01; 76(17):4970-80.
Score: 0.024
-
Squire SE, Chan MD, Marcus KJ. Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J Neurooncol. 2007 Jan; 81(1):97-111.
Score: 0.012